The halt will remain in place until the opening of trade on Monday 24th April 2017, or earlier if an announcement is made to the market.
View full OBJ profile View Profile
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine
Its SkinBiotix cream was assessed for cellular toxicity
The Phase II study of its PQ Grass immunotherapy, an aluminium-free, ultra-short course hay fever treatment, is designed to evaluate dose response and safety